3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Phase 2
1
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Head & Neck
1
Genitourinary
1
Endocrine
1
CNS
1
Conditions
Wilms Tumor
1
Uveal Melanoma
1
Thyroid Cancer, Papillary
1
Sarcoma, Ewing
1
Sarcoma
1
Salivary Gland Neoplasms
1
Recurrence
1
Neuroblastoma
1
Nephroma, Mesoblastic
1
Neoplasm Metastasis
1
Medulloblastoma
1
Glioma
1
Central Nervous System Neoplasms
1
Brain Neoplasms
1
Interventions
Temozolomide
26
Radiotherapy
10
Bevacizumab
10
Carboplatin
6
Irinotecan
5
pembrolizumab
4
Radiation
4
Nivolumab
4
IL13-PE38
4
temsirolimus
3
Surgical Procedures, Operative
3
Magnetic Resonance Spectroscopy
3
Immunotherapy, Adoptive
3
Erlotinib Hydrochloride
3
Aminolevulinic Acid
3
trametinib
2
olaparib
2
lutetium Lu 177 dotatate
2
fludarabine
2
dabrafenib
2
cemiplimab
2
abemaciclib
2
Vorinostat
2
Transurethral Resection of Bladder
2
Sirolimus
2
Radiotherapy, Intensity-Modulated
2
Radiosurgery
2
Imatinib Mesylate
2
Flucytosine
2
Cyclophosphamide
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Glioma
×
entrectinib
×
Clear all
NCT02650401
2026-03-25
STARTRK-NG
Hoffmann-La Roche
Phase 1/2
Active not recruiting
69 enrolled
1 FDA